HypoPet is a Swiss biotech company engaged in the research, development, manufacture and licensing of therapeutic vaccines for major unmet needs in companion animal medicine; allergy, inflammation, pain, cardiovascular and metabolic disease and cancer. HypoPet has developed and patented a recombinant virus-like particle vaccine platform, which can be used to induce long-lived antibodies that specifically target key molecules that drive chronic diseases. With our technology we aim to leverage the profound success achieved with human monoclonal antibodies into cost-effective treatments for pets.
Company Details
- Founded
- 2013
- Address
- Wagistrasse 12, Schlieren,zürich 8952,switzerland
- hy****@****opet.ch
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- hypopet.ch
- HQ
- Schlieren, Zürich
Hypopet Ag Questions
Hypopet Ag's website is hypopet.ch
Hypopet Ag's LinkedIn profile is https://ch.linkedin.com/company/hypopet
Hypopet Ag's industry is
Biotechnology Research
Hypopet Ag's top competitors are
Scaski Sgps (Unipessoal), Lda.,
Track & Street Corner - Tscgroup Ltd,
Saiba Animal Health Ag,
Gausta Ab,
Brazgil Studio,
Evax Ag,
Aximech,
Boehringer Ingelheim,
Ringtail Security,
Swedepak Ab.
Hypopet Ag's support email address is hypopet@hypopet.ch
Hypopet Ag's categories are Biotechnology Research
Hypopet Ag's founding year is 2013
